Sponsors

Vivlion offers PRCISR™ CRISPR screening solutions to advance research in functional genomics and drug discovery. Vivlion's 3Cs technology enables the production of uniformly distributed gRNA libraries in single or combinatorial format. Solutions range from pooled and arrayed gRNA.

For more than 35 years, Integrated DNA Technologies, Inc. (IDT) has been empowering genomics laboratories with an oligonucleotide manufacturing process unlike anyone else in the industry, with the most advanced synthesis, modification, purification, and quality control capabilities available. Since its founding in 1987, IDT has progressed from a leading oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP* services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. As the company seeks to fulfill its mission of accelerating the pace of genomics, the important acquisition of Archer™ NGS Research Assays was completed in Dec. 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people.

With extensive experience in nucleic acid therapeutics, Axolabs provide gene editing services, including sgRNA synthesis (mg to multigram [nonGMP/GMP], up to 150-nt, conjugates), molecular biology (testing of in vitro activity and editing efficiency), and analytics (RNA characterization, bioanalysis under GLP/GCP). Our expertise ensures high-purity and scalable therapeutic solutions.

ChemoMetec is a leading manufacturer of high-precision cell counting and analysis equipment.

Our robust Xcytomatic® and NucleoCounter® instruments are the most precise automated cell counters on the market and enable the development of reproducible processes and cGMP manufacturing of biological products.

The stellar support we offer from our field application scientists and engineers help thousands of biopharma customers integrate commercial-ready cell counting processes across sites. No matter the sample, location or user, our technology ensures consistent performance.

Agilent has been manufacturing oligonucleotide therapeutics since 2006. Our cGMP facilities support clinical-grade production of CRISPR sgRNA, siRNA, and antisense, from grams to kilograms. In 2027, Agilent will launch a dedicated CRISPR sgRNA manufacturing train. The BioVectra CDMO acquisition added sterile fill-finish and biologics capabilities for comprehensive gene editing.

Ampliqon is a global leader in production of PCR Enzymes and custom made laboratory reagents.

Bio-Rad is a global leader in developing, manufacturing, and marketing products for the life science research and clinical diagnostic markets. Bio-Rad provides instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education.

baSeq is developing intuitive LLM-based software to streamline the analysis of complex biological data, making specialist knowledge superfluous and lowering the cost of scRNA-seq research.

Unleash the full potential of your nucleic acid technology!

BioSpring is a leading CDMO specializing in the manufacturing and analysis of synthetic nucleic acids and mRNA for diagnostic and therapeutic applications. With 650 employees we support biotech and pharmaceutical companies across all stages of drug development with high-quality cGMP manufacturing and analytics. Our platform technologies enable rapid process adaptation, ensuring efficient, scalable production. Recognized for technological leadership in gene editing and beyond, we provide drug substances for innovative nucleic acid-based therapies, including several approved drugs.

Broken String Bioscience’s technology platform, INDUCE-seq® supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

Caszyme is a biotech company based in Vilnius, Lithuania, specializing in CRISPR-Cas gene editing technology development, application, and novel Molecular Tools. We empower partners looking to leverage CRISPR with our deep expertise, backed by a highly flexible platform of characterized nucleases, enabling the development of market-ready products across multiple industries.

Countagen develops cutting-edge gene editing analysis tools to enable and accelerate access to the transformative power of gene editing. Our mission is to pioneer excellence in the development and discovery of gene and cell therapies.

GeneAbacus, our flagship product, utilizes the unique technology of padlock probes and rolling circle amplification to speed up and simplify the gene targeting validation process. This assay removes the need for PCR and can be done completely in-house with standard laboratory instrumentation. We are able to bring extracted DNA to quantified data in under 5 hours, with minimal hands-on time and digital quantification precision.

Click to learn more.

CRISPR QC provides cutting-edge quality control solutions for CRISPR-based manufacturing through its CRISPR Analytics Platform™. These in vitro functional assays deliver real-time data on RNP formation, DNA binding, and cleavage activities, enabling organizations to optimize editing efficiency, verify reagent performance, and streamline bioprocessing workflows.

GenScript Biotech offers comprehensive gene synthesis, DNA and RNA oligo synthesis with specialties in CRISPR sgRNA/NGS/qPRC/tRNA/siRNA oligos, IVT mRNA/circRNA synthesis and LNP formulation, as well as peptide synthesis, protein and antibody production services. GenScript Biotech can also offer peptides as well as CRISPR services from research use to cGMP needs.

With more than 26 years of experience in the nucleic acid industry, Hongene is a specialist CDMO and raw materials supplier, committed to providing high-quality and high-value products and services with best-in-class lead times. Our world-leading manufacturing capacity of phosphoramidites is 58 tons and 54,000 liters for NTP per year, sufficient to support customers from small-scale to commercial production.

HuidaGene Therapeutics utilizes its proprietary CRISPR-based HG-PRECISE platform to develop potentially curative genome medicines.

Lonza Bioscience Solutions provides life science researchers in academic and government institutions as well as major biotech and pharmaceutical organizations worldwide with the tools they need to develop and test critical disease-treating drugs and therapies, from basic research to final product release, including cell culture and discovery technologies, quality control tests and software for biomanufacturing.

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery and commercialization of next-generation cell therapeutics. MaxCyte builds best-in-class technology to facilitate complex engineering of a variety of cells. Let’s Build Better Cells Together.

MedChemExpress (MCE) is a leading global provider of research chemicals and bioactive compounds, offering an extensive product portfolio to esteemed research institutes, laboratories, biotech firms, and pharmaceutical companies worldwide. Our diverse catalog includes 60,000+ inhibitors and agonists, 36,000+ oligonucleotides, and 20,000+ life science products, including recombinant proteins, peptides, antibodies, fluorescent dyes and kits etc. We also provide a one-stop screening library service to meet all your drug discovery research needs. Supported by a team of seasoned professionals, we are committed to delivering friendly and proficient service to cater to your unique requirements.

The McDonnell Genome Institute integrates cutting-edge ‘omics technologies with expert knowledge to support you as a trusted partner. Explore our comprehensive solutions, including NGS, gene editing, stem cell biology, proteomics, and high-content imaging — tailored to meet your needs.

Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure, characterize, and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. The company’s Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide. A Tapestri assay recently entered GMP qualification and validation, indicating that single-cell analysis is on its way to routine use in clinical trials to support the next wave of life-saving CGT treatments.

At Moligo we have developed a novel enzymatic synthesis technology that generates DNA strands with unprecedented purity, length and complexity, and at industrial scale. We support partners developing new gene-based therapies and technologies with the mission of making them better, safer and accessible for everyone.

NanoEntek possesses a key piece of Bio-MEMS technology that seamlessly integrates biotechnology with Micro-electro Mechanical Systems(MEMS), which is heralded as the most advanced technology in the 21st century. Our company has over 100 patents related to NT-IT-BT (nanotechnology-information technology-biotechnology) convergence technology in Korea and abroad. NanoEntek has developed by inventing creative and innovative products over 20 years. NanoEntek will continue to innovate and share our creative thoughts to develop our world more and more.

RedShiftBio’s fully automated AuroraTX system utilizes a 96-well plate, 50ul of sample, and provides both structure and stability, measured with thermal ramping, for your RNA, DNA, proteins, and peptides. AuroraTX is complemented by a full analytics software suite which allows for rapid and straightforward data analysis, with minimal training required.

ST Pharm is a top-tier CDMO with an integrated technology platform supporting clinical- and commercial-scale production of small molecule API, next-generation therapeutics in oligonucleotides, mRNA, and circRNA. ST Pharm can provide process development, analytical development, and manufacturing (GMP and Non GMP) services and have established non-viral CRISPR Cas production capabilities.

Synthego is your CRISPR Guide, providing unparalleled access to CRISPR solutions at scale for applications from Discovery to Clinic. We strive to accelerate the therapeutic development process with best-in-class CRISPR solutions, simplified licensing, & expert guidance, driving the adoption and success of CRISPR-based therapies to benefit all patients.

Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing accepted in 2022 followed in 2025 with the world’s first GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing innovation. With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies.